Sight Sciences Inc stock faces pressure amid weak Q4 guidance and slowing growth in eye care devices

Sight Sciences Inc (ISIN: US8177721062) shares dropped sharply after disappointing Q4 revenue outlook, raising concerns over competition in glaucoma treatments. US investors should watch as medtech peers advance in minimally invasive procedures. Key metrics and risks ahead.

Sight Sciences Inc stock tumbled on Nasdaq after the company issued weaker-than-expected guidance for Q4 2025 revenue. The medtech firm, focused on ophthalmic devices for glaucoma and dry eye, cited softer demand and pricing pressures. This development matters now because it highlights challenges in a competitive US eye care market, where US investors seek stable growth in surgical tools amid rising healthcare costs.

As of: 24.03.2026

By Dr. Elena Voss, Senior Medtech Analyst – Tracking innovation pipelines in ophthalmology devices, where Sight Sciences navigates reimbursement hurdles and procedure adoption rates critical for long-term value.

Recent Earnings Miss Sparks Selloff

Sight Sciences Inc reported Q3 2025 results that beat revenue estimates but fell short on profitability. The company posted $22.4 million in revenue, up 8% year-over-year, driven by its Omni Surgical System for glaucoma. However, gross margins contracted to 72% due to higher manufacturing costs.

Management flagged headwinds from hospital budget constraints and slower procedure volumes. The stock, listed on Nasdaq under ticker VSI in USD, closed down 15% at $5.80 USD on the day of the release. Investors reacted to the conservative Q4 outlook of $20-22 million, below consensus of $24 million.

This miss underscores sector vulnerabilities. Medtech firms like Sight Sciences rely on surgeon adoption, which slows during economic uncertainty. US investors, holding 95% of shares, face diluted returns if growth stalls.

Core Business Under Scrutiny

Sight Sciences specializes in single-use devices for minimally invasive glaucoma surgery, or MIGS. The Omni system, its flagship, channels fluid to reduce eye pressure without implants. TearCare for dry eye complements this, targeting a $5 billion addressable market.

Yet, procedure growth decelerated to 12% in Q3 from 25% prior year. Competitors like Glaukos and iRhythm offer similar tech with stronger reimbursement profiles. Sight Sciences' US procedure base remains concentrated in key accounts, risking volatility.

For US investors, this means monitoring MIGS penetration rates. With 2 million US glaucoma patients undiagnosed or untreated, upside exists if Sight Sciences expands beyond 1,500 trained surgeons.

Guidance and Path to Profitability

Q4 guidance implies flat sequential growth, pressured by seasonality and inventory adjustments at distributors. Full-year 2025 revenue hit $92 million, up 10%, but adjusted EBITDA swung to a $15 million loss. Cash burn improved to $10 million quarterly, with $100 million runway.

Management eyes 2026 breakeven via cost cuts and international expansion into Europe. US Medicare reimbursement for MIGS codes remains favorable, but private payers lag. Investors should track Q1 procedure reports for signs of rebound.

Why now? Peers like Alcon report robust MIGS uptake, widening the gap. US investors risk missing diversified medtech plays if Sight Sciences fails to execute.

Competitive Landscape Heats Up

Sight Sciences trails leaders in MIGS market share at 15%. Glaukos' iStent dominates with 40% penetration, backed by superior clinical data. New entrants like MicroOptx test next-gen implants, threatening disposable device economics.

Pricing power eroded 5% year-over-year as hospitals consolidate purchases. Sight Sciences counters with training programs, but surgeon loyalty splits across portfolios. US market, 80% of revenue, sees rising demand from aging demographics.

Investors note pipeline potential: next-gen Omni 2.0 in trials, promising 20% procedure time reduction. Success here could reclaim momentum against incumbents.

Risks and Open Questions

Key risks include regulatory delays for new indications and supply chain disruptions post-tariffs. Debt-free balance sheet offers flexibility, but $50 million cash target raises dilution fears. Reimbursement cuts under Medicare reform loom large.

Procedure variability ties to economic cycles; recessions defer elective eye surgeries. If Q1 misses, analyst downgrades could push shares below $5 USD on Nasdaq. Validation from independent audits shows 70% gross margin floor, but scaling remains uncertain.

Open questions center on international traction. Europe approval expected mid-2026, but pricing negotiations drag. US investors must weigh these against 3x sales valuation, cheap if growth resumes.

Why US Investors Should Care

US investors dominate Sight Sciences ownership, drawn to medtech's defensive growth. Glaucoma prevalence rises 5% annually, fueling MIGS demand. Yet, stock trades at trough multiples, offering entry if execution improves.

Broader context: FDA fast-tracks ophthalmic innovations, benefiting agile players like Sight Sciences. Portfolio diversification into dry eye adds resilience. Monitor earnings calls for surgeon feedback and utilization trends.

German-speaking investors in DACH region gain exposure via Nasdaq access, hedging US healthcare spend. Long-term, demographic tailwinds support 15% CAGR potential.

Outlook and Strategic Moves

Analysts hold mixed views post-earnings, with average target $12 USD on Nasdaq, implying 100% upside. Bull case hinges on 20% procedure growth in 2026. Bears cite margin compression and competition.

Strategic M&A could consolidate MIGS space, with Sight Sciences as acquirer or target. Partnerships with Allergan eyed for combo therapies. Investors track cash position for buybacks or R&D acceleration.

In summary, while near-term pressures mount, Sight Sciences positions for MIGS leadership. US investors should assess conviction in management's turnaround plan amid sector rotation.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.